HER2+ Breast Cancer: Applying Recent Data Updates at ASCO 2024 into Clinical Practice

home / peer-exchange / her2-breast-cancer-applying-recent-data-updates-at-asco-2024-into-clinical-practice

A panel of experts on HER2+ breast cancer has a comprehensive discussion on recent data updates and how they might impact clinical practice.

EP. 1: Challenges in Diagnosing HER2+ Breast Cancer

By Joyce O’Shaughnessy, MD
Melinda L. Telli, MD

June 24th 2024

A panel of experts on breast cancer provide insights on challenges encountered during the diagnosis of HER2+ early breast cancer and discuss the role of immunohistochemistry and FISH testing.

EP. 2: Neoadjuvant Treatment Options in HER2+ Early Breast Cancer

By Joyce O’Shaughnessy, MD
Melinda L. Telli, MD

June 24th 2024

Ian Krop, MD, PhD, outlines his institution’s approach to utilizing neoadjuvant therapy in patients with HER2+ early breast cancer, and Melinda Telli, MD, discusses the role of surgery.

EP. 3: Preoperative Monitoring and Surgical Options for HER2+ Patients

By Joyce O'Shaughnessy, MD
Melinda L. Telli, MD

July 1st 2024

Kandace P. McGuire, MD, provides clinical insights on how patient monitoring practices inform discussions around surgical options, providing the potential for deescalating surgical management.

EP. 4: Clinical Impact of Subcutaneous Antibody-Drug Conjugates in HER2+ Breast Cancer

By Joyce O’Shaughnessy, MD
Melinda L. Telli, MD

July 1st 2024

Breast cancer specialists outline their institutions’ practices regarding the choice between subcutaneous and intravenous antibody-drug conjugates in patients with HER2+ breast cancer.